HRA Raising Game To Promote UK OTC Daily Contraceptive, Hopes US Switch Will Follow

HBW Insight speaks to HRA Pharma CEO David Wright about the company's recent UK Rx-to-OTC contraceptive pill switch, it's signifcance for the global women's health category and the implications for a similar switch the company is pursuing in the US. 

Contraceptive pill
• Source: Shutterstock

With the Rx-to-OTC switch of its Hana progestogen-only pill, France’s HRA Pharma recently became, alongside local player Maxwellia, the first company to offer British women an OTC daily contractive.

Both HRA’s Hana and Maxwellia’s Lovima desogestrel-based pills were launched at the end of July, after the UK Medicines and...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from United Kingdom

More from Europe